The GLP-1 receptor agonist semaglutide is currently part of Phase 3 trials as a therapy for MASH, following promising results from earlier studies regarding improvements in MASH without worsening fibrosis [22]. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatohepatitis.